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Abstract: Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid (PUFA) with 20 carbon atoms and 5 carbon-carbon
double bonds. Mammalian cells cannot synthesize long chain PUFAs such as EPA de novo, and, thus, the most effective way to enrich
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membrane phospholipids. Many beneficial effects of EPA supplementation have been noted, including (1) the potential to sensitize
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Introduction

Eicosapentaenoic acid (EPA) is an omega-3 polyunsaturated fatty acid (PUFA) with 20 carbon atoms and
5 carbon-carbon double bonds and is designated as
20:5 (ω-3) (Fig. 1). Mammalian cells cannot synthesize long chain PUFAs de novo, although EPA can be
synthesized from the essential fatty acid, α-linolenic
acid (ALA), 18:3 (ω-3), but conversion is minimal.1
The most effective way to enrich cells in EPA is by
dietary intake of fish oils.2
There is an active interest in understanding the
effects of dietary supplementation of EPA as evidenced
by the number of trials exploring the use of this substance in improving human health. For instance, with
respect to cancer, marine-derived lipids, such as EPA,
have the potential to sensitize tumors toward chemotherapy and enhance the cytotoxicity of certain anticancer drugs while preserving (or possibly) enhancing
the integrity of non-tumor tissue.3 PUFAs are known
to increase the presence of reactive oxygen species in
cancer cells and may contribute to improving neutrophil function thus enhancing the action of the innate
immune system.4 Further studies, however, are necessary to understand the mechanism whereby PUFAs
selectively sensitize tumor cells but not normal tissue toward chemotherapeutic drugs. Certain cancers
also lead to muscle loss or wasting (known as cancer
cachexia), with patients exhibiting reduced levels of
plasma omega-3 lipids that continue to decline over
the course of the disease.5 In this case, ongoing studies and trials indicate that fish oil supplements are
beneficial.6
There is also evidence from clinical trials and
randomized controlled trials that omega-3 fatty acid
supplementation decreases cardiovascular events
and the risk of cardiac death.7 The exact mechanisms
whereby omega-3 fatty acids contribute to decreasing
cardiovascular events are not clear, although effects
such as plaque stabilization,8 lipid profile alteration,9 triglyceride reduction,10 blood pressure reduction,11 inhibition of inflammation,12 or reduction in
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Figure 1. Structure of eicosapentaenoic acid (EPA), 20:5 (ω-3).
Note: Positions 7, 10, 13, and 16 indicate bis-allylic (methylenic)
hydrogen locations.
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a rrhythmia have been suggested.13 While the general
trend might be that these oils are beneficial, other
data indicate either insufficient evidence14,15 or even
an increased risk of cardiac death among patients
advised to take oily fish.16 The reasons for these
discrepancies are not clear, although potential concerns have been raised with regard to the quality
and rigor of some trials and the fact that in some
studies, patients were already receiving cardioprotective agents, for example, statins, such that further
supplementation with an omega-3 fatty acid may not
have had an impact.17,18
The effects of EPA supplementation have also
been investigated in patients with schizophrenia and
other mental health-related disorders. Certain lipids
are integral to the brain and significant membrane
abnormalities have been identified in the brains of
schizophrenic patients.19 The enzyme phospholipase A (PLA2), which releases arachidonic acid,
20:4 (ω-6) from membrane phospholipids is thought
to be overactive in schizophrenic brains. EPA supplementation may be beneficial since EPA may compete
with arachidonic acid for incorporation into membrane phospholipids and thus inhibit the enzyme.20
While a pilot study indicated that EPA is beneficial
in the treatment of schizophrenia,21 a more recent
meta-analysis of EPA data does not indicate a favorable role in schizophrenia and related psychological disorders.22 However, there may be confounding
effects in previous trials since a differential response
to EPA may occur depending on the history of pharmacological intervention, and an overall conclusion
may not be available as yet.
The role of EPA may be controversial, but the
indications are that EPA supplementation has, in
some cases, shown promise in ameliorating or preventing several conditions. Therefore, it becomes
important to understand the mechanisms of action.
However, before biological mechanisms can be fully
interpreted, it is essential to appreciate the chemical
nature of EPA and the transformations that EPA can
undergo. EPA shows reactivity toward oxygen, and is
known to autoxidize readily. In this study, we investigated the autoxidation of EPA by mass spectrometry and report a number of oxidized products and
their possible assignments. In this regard, we have
reviewed some of the schemes involving the autoxidation of EPA.
Lipid Insights 2013:6
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Methods
Materials

The sodium salt of cis-5,8,11,14,17-eicosapentaenoic
acid (EPA, $99% purity) was purchased from Sigma
Aldrich (St. Louis, MO). The sodium salt of EPA
was stored prior to use as received (under nitrogen)
in the solid form at −80 °C. Henceforth, the sodium
salt of EPA is referred to as “EPA.” Several portions
of EPA (0.5 mg) in glass vials (approximately 2 cm
in diameter and 6 cm in height) were allowed to oxidize in air at ambient temperature (22.2 °C–25.4 °C)
over 2 to 4 days under conditions of ∼12 hours light
and ∼12 hours dark. At the time of analysis, EPA was
dissolved in molecular grade water (1 mL) from Cellgro (distilled; deionized; DNAse, RNAse, and protease
tested). While the sodium salt of EPA has limited solubility, we found that the amounts used (i.e. 0.5 mg/mL
water) were fully soluble. Stock solutions were further
diluted with molecular grade water before introduction to the mass spectrometer. When analyzing fresh
EPA (i.e. when recording control mass spectra of the
sodium salt of EPA), all manipulations were performed
under nitrogen gas. In this regard, EPA was handled
under nitrogen gas and dissolved in molecular grade
water that had previously been purged with nitrogen.

Mass spectrometry

Native EPA and air-oxidized EPA samples were prepared as indicated above and dissolved in molecular grade water (0.17 mM). Samples were analyzed
using an Applied Biosystems MDS SCIEX API 2000
instrument (AB SCIEX, Framingham, MA). The mass
spectrometer was operated in negative ion mode with a
mass range of m/z 250 to 600 amu, using a declustering
potential (DP) of −60.0 V, a focusing potential (FP) of
−400.0 V, and an entrance potential (EP) of −100.0 V.
Nitrogen was used as both the sheath gas and the auxiliary gas. Data acquisition and analysis were performed using Analyst software, version 1.4. Samples
were introduced via syringe injection at a flow rate of
10.00 µL/min. Spectra (100 cycles) were accumulated
over a 5-minute period.

Results
Mass spectral analysis of autoxidized EPA

The sodium salt of EPA, a white powder, oxidizes
readily in air as evidenced by a change in color to
Lipid Insights 2013:6

a yellow solid within a short period of time. When
this process was monitored by mass spectrometry,
several new species were observed within 0 to 4 days
of exposure to air (Fig. 2). Mass spectral analysis of
fresh native EPA gives rise to a main peak at 300.9 m/z
(exact mass of acidic form of EPA = 302.2 amu),
which corresponds to the deprotonated anion, that is,
(exact mass-H)/z. The main peak at 300.9 m/z displays the correct isotopic pattern, giving two shoulders at 302.1 m/z (exact mass = 303.2 amu) and
303.1 m/z (exact mass = 304.2 amu) (Fig. 2, blue
spectrum). While care was taken to exclude oxygen,
some small peaks mainly centered at 317.0 m/z and
333.1 m/z were also observed, indicating that either
the EPA contains some oxidized product, or else a
small amount of oxidation occurred during the handling process. However, mass spectrometric analysis
of several samples of fresh native EPA consistently
revealed small amounts of oxidized product.
Oxidation over several days revealed the formation of species with higher masses (Fig.2 A–C). For
example, after 2 days of air oxidation, small clusters of ions centered at 317.0, 333.1, 348.9, and
365.0 m/z were observed to increase with a corresponding decrease of native EPA at 300.9 m/z
(Fig. 2B, red spectrum). After 4 days of air oxidation,
new species clustered at 380.7 m/z and 396.7 m/z
appeared, accompanied by a decrease of parent EPA
(300.9 m/z) together with a decrease in ions centered
at 317.0 and 331.1 m/z (Fig. 2B, green spectrum).
Notably, the average difference in mass between the
peaks of greatest intensity in each cluster group is
15.97 ± 0.07 amu, corresponding to mass of an oxygen atom. Thus, the groups of ions centered at 317.0,
333.1, 348.9, 365.0, 380.7, and 396.7 m/z represent,
respectively, the addition of 1, 2, 3, 4, 5, and 6 oxygen atoms to native EPA. The facts that (1) the relative intensities of these peaks changed with time and
(2) higher masses were observed after longer exposures to air indicate that their presence is real and not
an artifact of the mass spectrometric process. In some
cases, where the peaks representing oxidized EPA ions
are larger, it is possible to discern an isotopic pattern
(which is also clearly apparent in non-oxidized EPA
at 300.9 m/z).
While each cluster group can be ascribed to an
ion having 1 to 6 additional oxygen atoms compared
with the parent ion, it also appears that species within
23
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Figure 2. Air oxidation of EPA leads to products of increased mass. Mass spectra of (A) native EPA (blue), and EPA oxidized in air for 2 and 4 days
(red and green spectra, respectively). Native EPA gives a peak at 300.9 m/z (amu). (B) Magnified view of the same mass range as (a), with the mass of
the dominant peak in each cluster group identified as the addition of 1, 2, 3, 4, 5, or 6 oxygen [O] atoms to EPA. (C) Magnified view of the 325–365 m/z
range, highlighting the separation of peaks in each cluster of ions by 2.05 ± 0.04 (amu), representing the loss or gain of 2 hydrogen atoms. Peaks
may also represent ions formed upon loss of water as, for instance, indicated for a species of mass 365.0 m/z losing H2O to yield a species of mass
346.8 m/z.
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each cluster group are separated by 2.05 ± 0.04 amu
(Fig. 2C). This difference represents either an incremental gain or loss of 2 hydrogen atoms. While autoxidation pathways are covered in more detail below,
possible mechanisms could include ring-opening of
cyclic peroxides resulting in the formation of hydroxy
compounds (i.e. gain of 2 hydrogen atoms) or, conversely, keto formation from an alcohol (i.e. loss of
EPA
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The species that result from autoxidation of
EPA appeared and disappeared at different rates,
as shown by plots of peak intensity versus time
(Fig. 3). The peak intensity of the parent EPA ion
decreased over 4 days (Fig. 3A). Several species in
the cluster groups with 1 or 2 oxygen atom additions
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Figure 3. Variation of peak intensity with time. Peak intensities are monitored over time (0–4 days) to indicate the rate at which ions appear or disappear.
(A) Parent EPA ion at 300.9 m/z and the cluster group of ions with (B) 1 oxygen [O] atom addition, (C) 2 oxygen atoms, (D) 3 oxygen atoms, (E) 4 oxygen
atoms, (F) 5 oxygen atoms, and (G) 6 oxygen atoms.
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( designated as EPA + 1[O] and EPA + 2[O] in Fig. 3B
and C, respectively) also disappeared over 4 days.
Conversely, some species (indicated by peaks at 312.9,
326.8, 328.8, and 330.8 m/z) were formed during this
time, perhaps from precursors that are being reduced
in intensity. The clusters of peaks representing the
addition of 3, 4, 5, and 6 oxygen atoms all increased
with time (Fig. 3D–G). Notably, the higher-mass species (e.g. EPA + 5[O] and EPA + 6[O]) only started to
appear after 2 days, indicating that the higher-mass
oxidized species are formed from the lower-mass oxidized species and that oxygen addition is a sequential
process.
Comparison of the total intensity of peaks in the
290 to 450 m/z region shows that ∼30% of the total
intensity is lost after 2 days and is further reduced
after 4 days (∼50% that of the original spectrum).
While a comparison of total intensity may not provide a consistent method of comparing spectra, the
indication is that there is an overall loss of intensity.
Although the loss of intensity is not fully understood,
it is possible that some of the species formed are not
detected by the mass spectrometric process or else
occur at masses outside the region shown. Although
oxidized EPA appears soluble giving rise to clear,
yellow solutions, it is also possible that the solubility
of some of the oxidized species is limited.

Discussion

In this study, we sought to identify the types of products formed when the sodium salt of EPA is autoxidized in air at ambient temperature. To the best of
our knowledge, this represents the first study in which
the autoxidation process was allowed to occur in
the solid phase in the presence of air and light but
in the absence of any solvent or exogenously-added
peroxide/free-radical initiating species. Previous
mass spectrometric studies of in vitro oxidized EPA
products have involved the addition of free-radical
initiating compounds to EPA dissolved in organic
solvents.23,24 Gas chromatography coupled with mass
spectrometry (GC-MS) provides a sensitive method
for characterizing products of PUFA oxidation, but
often requires the derivatization of products prior to
analysis.25 To prevent additional modification that
may occur during the GC-MS process, an alternative
method may be used that utilizes liquid chromatography to separate compounds before being introduced
26

to the ion source and characterized by tandem mass
spectrometry (LC-MS/MS). These methods have previously been successfully applied to profiling oxidized
lipids, for instance, in plasma and urine samples.26,27
In the current study, we applied electrospray ionization mass spectrometry to the direct observation of
oxidized EPA species.
Our results indicated that species containing up to
6 oxygen atoms result from air oxidation (Fig. 2). In
addition to these species, we also observed ions that
were separated by 2.05 ± 0.04 amu from the main
peak of each cluster group (and, in some cases, by
18 amu between peaks of different cluster groups). In
order to make potential assignments, it is necessary
to consider schemes of oxygen addition and autoxidation, as described below.

Basic products of EPA autoxidation

Unsaturated fatty acids are susceptible to oxidation
due to the fact that the formation of a free radical on
a carbon atom located between 2 carbon-carbon double bonds (otherwise known as a bis-allylic position)
is remarkably stable.28 Thus, it is relatively easy to
remove a hydrogen atom from EPA to produce a radical that can interact with an oxygen molecule. EPA
has four bis-allylic moieties, centered at C-7, C-10,
C-13, and C-16 (Fig. 1).
Scheme 1 illustrates a mechanism of EPA oxygenation, which is based on the mechanism of arachidonic acid oxygenation.23 EPA is similar in structure
to arachidonic acid in that it has a 20-carbon backbone but, unlike arachidonic acid, EPA has 5 carboncarbon double bonds (versus 4 in arachidonic acid)
and is an omega-3 fatty acid (rather than arachidonic
acid which is an omega-6 fatty acid). Due to their
similarities in structure, similar mechanisms may
apply to oxygenation of both EPA and arachidonic
acid. Lipid oxidation can be initiated by certain transition metals, such as iron, but physiologically, lipid
oxidation may occur enzymatically in a selective
manner. For instance, oxygenation of arachidonic
acid by the cyclooxygenase enzymes (COX-1 and
COX-2) initiates the cascade leading to prostaglandin (PG) formation. Oxygenation by COX occurs
when arachidonic acid lies in the cyclooxygenase
channel with the C-13 position adjacent to tyrosine385 in the polypeptide backbone. The catalytic process involves tyrosine cation radical production,
Lipid Insights 2013:6
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Scheme 1. Mechanism of EPA oxygenation. Oxygenation of EPA (1) is
initiated by hydrogen abstraction of the C-13 position (2), allowing oxygen to add at C-11 (3), followed by endoperoxide formation (4), further
cyclization (5) and the addition of a second oxygen to produce a bicyclic
endoperoxide (6), which can be reduced to a F3 isoprostane (7). For simplicity, the stereochemistry of the structures is not shown.

which is responsible for stereoselective abstraction
of the 13-pro-S hydrogen from the C-13 position and
thus initiating oxygenation.29 EPA can readily replace
arachidonic acid in the lipid bilayer and act as a substrate for the COX enzymes.
Lipid Insights 2013:6

Physiologically, EPA oxidation is expected to
occur enzymatically but, under situations of oxidative stress, nonenzymatic routes may also occur in
living systems.30 EPA is prone to peroxidation and
can be oxidized nonenzymatically, often resulting in
prostaglandin-like substances, called isoprostanes.24
When only lipid radicals and oxygen are involved,
the process is known as “autoxidation,” but similar mechanisms may be involved in both enzymecatalyzed lipid oxidation and autoxidation. Thus,
Scheme 1 illustrates a mechanism of EPA oxygenation with initial hydrogen abstraction occurring at
the C-13 position. Rearrangement leads to radical
formation at the C-11 position with subsequent radical trapping of oxygen, followed by the formation
of a 5-membered endoperoxide ring, cyclization,
further rearrangement and a second oxygenation at
C-15. Reduction results in the production of F3 isoprostane (also known as PGF3α).
An important difference between enzymecatalyzed lipid oxygenation and autoxidation is that
enzyme-directed oxygenations are stereospecific.
Autoxidation of arachidonic acid is well elucidated
and can occur at different bis-allylic positions.31 In
this regard, autoxidation of EPA can, in principle, be
initiated at any of the C-7, C-10, C-13, or C-16 sites.23
Novel oxidation products of EPA have previously
been identified using mass spectrometric techniques
including Ag+ coordination ionspray and atmospheric
pressure chemical ionization mass spectrometry.23
Importantly, these oxidation products were observed
both in vitro and in vivo.23 Scheme 2 illustrates the
collection of hydroperoxyeicosapentaenoic acid
(HpEPE) and hydroxyeicosapentaenoic (HEPE) isomers that could form following initiation at the 4 different bis-allylic positions. According to Scheme 2,
the peaks observed at 317.0 and 333.1 m/z (Fig. 2)
represent the addition of 1 and 2 oxygen atoms to EPA,
respectively, and can potentially be ascribed to HEPE
and HpEPE isomers of EPA (exact masses = 318.2
amu and 334.2 amu, respectively).

Monocyclic and serial cyclic
peroxide formation

Monocyclic and serial cyclic peroxide products of
EPA have previously been investigated.23 Scheme 3A
represents the type of monocyclic (1,2-dioxolane)
and serial cyclic peroxides that can, in principle, form
27
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Scheme 2. Hydrogen abstraction at C-7, C-10, C-13, and C-16 yields a wide variety of hydroperoxyeicosapentaenoic acid (HpEPE) and hydroxyeicosapentaenoic acid (HEPE) products. Hydrogen abstraction of EPA (1) at C-7, leads to the 5- and 9-series of HEPE and HpEPE products (8–11); at C-10
results in the 8- and 12-series of HEPE and HpEPE products (12–15); at C-13 yields the 11- and 15-series of HEPE and HpEPE products (16–19), and at
C-16 leads to the 14- and 18-series of HEPE and HpEPE products (20–23).

when initial hydrogen abstraction occurs at C-13, followed by rearrangement to yield a carbon radical at
C-11 to allow initial oxygen addition, that is, (1) to (3)
in Scheme 1. In this particular example, EPA can potentially gain 4 oxygen atoms (monocyclic peroxide), or
28

else peroxidation can go further yielding a structure
with 6 oxygen atoms (serial cyclic peroxide).
The position of initial hydrogen abstraction and
subsequent location of the carbon radical (with respect
to its proximity to carbon-carbon double bonds)
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Scheme 3. Oxygenation of EPA yields monocyclic and serial cyclic peroxides. (A) Following hydrogen abstraction from C-13 of EPA (1) and subsequent
endoperoxide radical formation (4), oxygen addition can occur at the C-8 position leading to the formation of a monocyclic peroxide (24), with possible
further oxygen addition at C-5 yielding a serial cyclic peroxide (25). (B) Hydrogen abstraction from C-7 leading to a radical on C-9 allows addition of
4 oxygen atoms (26), 6 oxygen atoms (27) or 8 oxygen atoms (28).

d etermine the extent of peroxidation and dioxolane
formation. For instance, structures are possible with
only 2 oxygen atom additions (i.e. when oxygen first
adds to a carbon radical on either C-5 or C-18) or
up to 8 oxygen atom additions (i.e. when oxygen
first adds to C-9 or C-14 radicals). For example,
hydrogen abstraction at C-7 leading to a radical on
C-9 allows addition of 4, 6, or 8 oxygen atoms, as
shown in Scheme 3B. When hydrogen abstraction at
Lipid Insights 2013:6

C-7 instead leads to radical formation on C-5, only
2 oxygen atom additions are possible with the result
that 5-HpEPE is formed.
In summary, depending on the position of carbon radical formation, it is possible to form HpEPEs
(2 oxygen atoms; exact mass = 334.21 amu),
monocyclic peroxides (4 oxygen atoms; exact
mass = 366.20 amu) and serial cyclic peroxides containing 2 dioxolane rings (6 oxygen atoms, exact
29
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mass = 398.19 amu) or 3 dioxolane rings (8 oxygen
atoms, exact mass = 430.18 amu). As these rearrangements and additions occur, EPA, which is not initially
conjugated, becomes a partially conjugated system.
Upon reduction of the hydroperoxyl moiety to yield a
hydroxyl group, it is possible to form the corresponding dioxolane structures with 1, 3, 5, and 7 oxygen
atoms (exact masses = 318.22, 350.21, 382.20, and
414.19 amu, respectively). The mass spectra did not
yield evidence of a structure corresponding to 8 oxygen
atom additions (exact mass = 430.18 amu), but it was
possible to observe a species with m/z = 413.0, potentially indicative of a structure with 7 oxygen atoms
(exact mass = 414.19 amu; data not shown).

Hydrogen abstraction at multiple
bis-allylic carbon positions

Hydrogen abstraction that occurs at multiple bisallylic carbon positions in EPA can result in structures that contain multiple hydroxyl and/or peroxyl
adducts. This is illustrated in Scheme 4 for 5-HpEPE
that results from initial hydrogen abstraction at C-7.
Subsequent removal of a hydrogen atom from C-10
results in diHpEPE, which has another bis-allylic
position at C-16 that can undergo further hydrogen
abstraction. The resulting structures include triHpEPE and triHEPE. The triHEPE compounds are
also known as resolvins and have been found to have
anti-inflammatory properties.32–34 Notably, in human
endothelial cells, aspirin therapy causes COX-2 to
switch its catalytic activity from forming prostanoids
to producing specific HEPEs and novel trihydroxycontaining resolvins.32 In particular, 5,12,18-triHEPE,
also known as RvE1, has been associated with having
potent anti-inflammatory and analgesic properties.35

Products of enzymatic oxygenation
versus autoxidation

EPA can readily replace arachidonic acid in the lipid
bilayer and act as a substrate for the COX enzymes.
When arachidonic acid is the COX substrate, the
prostaglandin (PG-2) series of products is formed,
where the number 2 corresponds to the number of
carbon-carbon double bonds in the product. However,
when COX metabolizes EPA, the PG-3 series is
formed, with products containing 3 double bonds.36
Eicosanoids that are produced with arachidonic acid
30

as the initiating substrate are often associated with
proatherogenic and proinflammatory properties. In
contrast, eicosanoids derived from EPA are associated with less biological activity and therefore have
less of an impact on the process of inflammation
or proliferation.37 For instance, oxidized EPA significantly inhibited human neutrophil and monocyte
adhesion to endothelial cells by preventing expression
of the endothelial adhesion receptor via a mechanism
involving activation of the peroxisome proliferatoractivated receptor α (PPARα) and subsequent inhibition of NF-κB.38,39
Scheme 5 indicates that following bicyclic
endoperoxide (PGG3) formation, reduction occurs
forming PGH3, which can then be converted to several different types of eicosanoids, depending on the
available enzymes. In the presence of PGE synthase
(PGES) or PGDS, the products PGE3 and PGD3 can
form. Interestingly, it has previously been noted that
both PGE2 and PGD2 (the analogous products of
arachidonic acid metabolism) can form independent
of COX.30 In general, although the products that
result from enzymatic catalysis and autoxidation
may be similar, there may be important distinctions
in cis-trans orientations of side chains with respect
to the prostane ring, with non-enzymatic routes
favoring racemic mixtures. However, for COX-independent formation of PGE2 and PGD2, the products
were found to be identical to COX-derived PGE2
and PGD2.30 Thus, it may be possible for PGE3 and
PGD3 to result from autoxidation. PGA3 and PGJ3
(not shown) result from dehydration of PGE3 and
PGD3, respectively. Interestingly, it has previously
been found that incubation of EPA with free-radical
generating compounds in ethanol leads to the identification by mass spectrometry of PGA3 and PGJ3like products (termed A3/J3 isoprostanes).24 Thus,
products similar to PGA3 and PGJ3 may also result
during autoxidation.
Further products requiring enzymatic catalysis
include PGI3 (catalyzed by prostacyclin synthase),
which is likely unstable and converts to 6-ketoPGF3α (as PGI2 converts readily to 6-keto-PGF2α).
Importantly, the arachidonate-derived PGI2 is a potent
vasodilator and inhibitor of platelet aggregation.
Platelet-derived thromboxane synthase would convert PGH3 to thromboxane B3, the stable hydrolysis
product of TxA3. Notably, the arachidonate-derived
Lipid Insights 2013:6
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Scheme 4. Hydrogen abstraction at multiple bis-allylic carbon positions yields a mix of hydroxy and hydroperoxy products. Initial hydrogen abstraction at
C-7 results in 5-HpEPE (8), which can be reduced to 5-HEPE (9), or alternately, be subject to removal of a hydrogen atom at C-10 to form diHpEPE (30).
Further hydrogen abstraction at the bis-allylic position at C-16 results in the formation of structures that include triHpEPE (34) and triHEPE (37), as well
as other structures (and isomers) containing hydroxyl and peroxyl groups.

TxA2 has properties completely opposed to PGI2, in
that it is a potent inducer of platelet aggregation and
vasoconstrictor. A diet rich in EPA has been found to
lead to both PGI3 and TxA3 production and a concomitant reduction in thrombogenic TxA2.40
Lipid Insights 2013:6

Possible assignments of EPA
autoxidation products

Possible assignments of EPA autoxidation products
observed by mass spectrometry are listed in Table 1.
Compounds, outlined in Schemes 1–5, that result from
31

Jordan and Upmacis
COOH

O
O
OOH

(6)

Bicyclic endoperoxide (PGG3)
Exact mass = 366.20

COOH

O
O

H2 O

OH

(38) PGH3
Exact mass = 350.21
OH

O
COOH

COOH

HO

COOH

HO
OH

O
OH

(39) PGE3
Exact mass = 350.21

(42) TxB3
Exact mass = 368.22

O

HO
COOH

HO

OH

(41) PGI3
Exact mass = 350.21

O
OH

(40) PGD3
Exact mass = 350.21

2O

HO

COOH

2O

O

O
COOH

HO
OH

(44) 6-keto-PGF3
Exact mass = 368.22
OH

(43) PGA3
Exact mass = 332.20
Scheme 5. EPA metabolism by cyclooxygenase and other enzymes. Following bicyclic endoperoxide (PGG3) formation (6), reduction occurs forming
PGH3 (38), which can then be converted to several types of eicosanoids, in the presence of different enzymes. PGE synthase (PGES) or PGDS converts
PGH3 to PGE3 (39) and PGD3 (40), respectively. PGA3 (43) and PGJ3 (not shown) result from dehydration of PGE3 (39) and PGD3 (40), respectively.
Prostacyclin synthase converts PGH3 to PGI3 (41), which is likely unstable and dehydrates to 6-keto-PGF3α (44). Platelet-derived thromboxane synthase
converts PGH3 to thromboxane B3 (42), the stable hydrolysis product of TxA3.

non-enzymatic oxidation of EPA include HEPEs,
HpEPEs, monocyclic peroxides, bicyclic endoperoxides, serial cyclic peroxides, and potentially a series
of compounds with several hydroxyl or peroxyl moieties are included as possible products. Table 1 shows
that several isomers are possible for a single peak (and
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not all possible isomers are considered). Other species
were also noted that are incrementally 2.05 ± 0.04 amu
lower or higher in mass than the main ions in each
cluster group representing a gain of 1–6 oxygen atoms
(Fig. 2). This mass is consistent with 2 hydrogen
atoms. Possible mechanisms that involve a gain of
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Table 1. Examples of possible assignments of mass spectrometric peaks.
Observed mass
(anion) m/z (amu)

Formula

Possible assignments of the neutral form

Exact mass
(amu)

300.9

C20H30O2

302.22

317.0

C20H30O3

EPA (1)
1 oxygen addition
HEPE (Scheme 2) (9), (11), (13), (15), (17), (19), (21), (23)

330.8
333.1

C20H28O4
C20H30O4

348.9

C20H30O5

351.0

C20H32O5

365.0

C20H30O6

380.7

C20H30O7

396.7

C20H30O8

2 oxygen additions
PGA3 (PGJ3) (Scheme 5) (43)
HpEPE (Scheme 2) (8), (10), (12), (14), (16), (18), (20), (22)
diHEPE (Scheme 4) (32)
3 oxygen additions
Hydroxy-HpEPE (Scheme 4) (31)
triHEPE (Scheme 4) (37)
PGH3 (Scheme 5) (38), PGE3 (39), PGD3 (40)
F3 isoprostane (Scheme 1) (7)
4 oxygen additions
Bicyclic endoperoxide, PGG3 (Scheme 1) (6)
diHpEPE (Scheme 4) (30)
dihydroxy-HpEPE (Scheme 4) (35)
Monocyclic peroxide (Scheme 3) (24), (26)
5 oxygen additions
Hydroxy-diHpEPE (Scheme 4) (36)
6 oxygen additions
Serial cyclic peroxide (Scheme 3) (25), (27)
triHpEPE (Scheme 4) (34)

2 hydrogen atoms include ring-opening of cyclic
peroxides resulting in hydroxyl compounds or,
conversely, keto formation from an alcohol involves
a loss of 2 hydrogen atoms. Dehydration could also
contribute, as this would result in a loss of 18 amu.
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